公开(公告)号：EP4438040A1

公开(公告)日：2024-10-02

申请号：EP22864522.2

申请日：2022-08-30

申请人： Japan Tobacco Inc.

发明人： YAMAKAWA, Maki ,  SUZAWA, Koichi ,  YAMASHITA, Tomoya ,  UENO, Hiroshi ,  MANABE, Tomoyuki

IPC分类号： A61K31/424 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61P3/00 ,  A61P3/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P21/00 ,  A61P25/00 ,  A61P25/02 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07D498/04 ,  C07D519/00

CPC分类号： A61K31/424 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P21/00 ,  A61P25/28 ,  A61P25/00 ,  A61P25/02 ,  A61P27/06 ,  A61P35/00 ,  A61P43/00 ,  C07D471/14 ,  C07D487/14 ,  C07D498/04 ,  C07D498/14 ,  C07D519/00

摘要： The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I], the formula [II] or the formula [III], or a pharmaceutically acceptable salt thereof:


wherein each symbol is as defined in the DESCRIPTION.

公开(公告)号：EP4116301A1

公开(公告)日：2023-01-11

申请号：EP21764169.5

申请日：2021-03-03

申请人： Japan Tobacco Inc.

发明人： SUZAWA, Koichi ,  FUJISHIMA, Yuki ,  YAMAKAWA, Maki ,  UENO, Hiroshi ,  MANABE, Tomoyuki

IPC分类号： C07D471/04 ,  A61K31/424 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12

摘要： The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral artery disease, intermittent claudication, chronic obstructive pulmonary disease s, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I-a], or a pharmaceutically acceptable salt thereof:

wherein each symbol is as defined in the DESCRIPTION.

公开(公告)号：EP2202216B1

公开(公告)日：2012-06-27

申请号：EP08841970.0

申请日：2008-10-24

申请人： Japan Tobacco Inc.

发明人： SHIMADA, Takashi ,  UENO, Hiroshi ,  TSUTSUMI, Kazuhiro ,  AOYAGI, Kouichi ,  MANABE, Tomoyuki ,  SASAKI, Shin-ya ,  KATOH, Susumu

IPC分类号： C07C59/72 ,  A61K31/41 ,  A61K31/421 ,  A61K31/426 ,  A61K31/44 ,  A61P3/10 ,  A61P43/00 ,  C07C235/34 ,  C07D213/64 ,  C07D257/04 ,  C07D263/32 ,  C07D277/20 ,  C07D277/34

CPC分类号： C07C59/72 ,  C07B2200/07 ,  C07C59/86 ,  C07C69/734 ,  C07C235/34 ,  C07C235/78 ,  C07C2602/50 ,  C07D213/64 ,  C07D213/643 ,  C07D257/04 ,  C07D263/32 ,  C07D277/20 ,  C07D277/34

摘要： Disclosed is a spiro-ring compound represented by the general formula [Ia], a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt thereof.

公开(公告)号：EP1953147A1

公开(公告)日：2008-08-06

申请号：EP06833441.6

申请日：2006-11-21

申请人： Japan Tobacco, Inc.

发明人： UENO, Hiroshi ,  SHIMADA, Takashi ,  AOYAGI, Kouichi ,  KATOH, Susumu ,  SHINKAI, Hisashi ,  MOTOMURA, Takahisa ,  KOMODA, Yasumasa ,  OTSUBAKI, Tomoko ,  SOEJIMA, Yuki ,  KAWAHARA, Iichiro

IPC分类号： C07D237/26 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/55 ,  A61K38/21 ,  A61K45/00 ,  A61P1/16 ,  A61P31/14 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

CPC分类号： C07D237/26 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/55 ,  A61K38/21 ,  A61K45/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  A61K2300/00

摘要： The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient:

wherein Q 1 is -N=, etc., Q 2 is -N-, etc., Q 3 is -N=, etc., Q 4 is -N-, etc., Q 5 is -N-, etc., R 1 is a hydrogen atom, etc., R 2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.

摘要翻译： 本发明旨在提供一种具有HCV进入抑制活性的新型杂环化合物及其药物用途。 本发明提供一种丙型肝炎治疗剂，其包含由下式[1]表示的杂环化合物或其药学上可接受的盐作为活性成分：其中Q 1为-N =等，Q 2为-N- 等等，Q 3为-N =等，Q 4为-N-等，Q 5为-N-等，R 1为氢原子等，R 2为氢原子 环等是任选具有取代基等的单环芳基，环B是任选具有取代基的单环芳基等。

公开(公告)号：EP2784074A1

公开(公告)日：2014-10-01

申请号：EP12827193.9

申请日：2012-08-30

申请人： Japan Tobacco, Inc.

发明人： MIURA, Tomoya ,  OGOSHI, Yosuke ,  UEYAMA, Kazuhito ,  MOTODA, Dai ,  IWAYAMA, Toshihiko ,  SUZAWA, Koichi ,  NAGAMORI, Hironobu ,  UENO, Hiroshi ,  TAKAHASHI, Akihiko ,  SUGIMOTO, Kazuyuki

IPC分类号： C07D401/12 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/454 ,  A61P3/10 ,  A61P43/00 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12

摘要： A compound of the following general Formula [Ib]:

, wherein each symbol is the same as defined in the description; or a pharmaceutically acceptable salt thereof.

摘要翻译： 下列通式[Ib]的化合物：其中每个符号与说明书中定义的相同; 或其药学上可接受的盐。

公开(公告)号：EP2202216A1

公开(公告)日：2010-06-30

申请号：EP08841970.0

申请日：2008-10-24

申请人： Japan Tobacco Inc.

发明人： SHIMADA, Takashi ,  UENO, Hiroshi ,  TSUTSUMI, Kazuhiro ,  AOYAGI, Kouichi ,  MANABE, Tomoyuki ,  SASAKI, Shin-ya ,  KATOH, Susumu

IPC分类号： C07C59/72 ,  A61K31/41 ,  A61K31/421 ,  A61K31/426 ,  A61K31/44 ,  A61P3/10 ,  A61P43/00 ,  C07C235/34 ,  C07D213/64 ,  C07D257/04 ,  C07D263/32 ,  C07D277/20 ,  C07D277/34

CPC分类号： C07C59/72 ,  C07B2200/07 ,  C07C59/86 ,  C07C69/734 ,  C07C235/34 ,  C07C235/78 ,  C07C2602/50 ,  C07D213/64 ,  C07D213/643 ,  C07D257/04 ,  C07D263/32 ,  C07D277/20 ,  C07D277/34

摘要： The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

摘要翻译： 由以下通式[Ia]表示的螺环化合物，其药学上可接受的盐或其溶剂化物